PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. - Fujita,T.; Doihara,H.; Kawasaki,K.; Takabatake,D.; Takahashi,H.; Washio,K.; Tsukuda,K.; Ogasawara,Y.; Shimizu,N. (Br J Cancer, 2006)